Cargando…
Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer
BACKGROUND: The increasing understanding of non-small cell lung cancer (NSCLC) biology over the last two decades has led to the identification of multiple molecular targets. This led to the development of multiple targeted therapies in the primary and secondary resistance setting and the epidermal g...
Autores principales: | Berz, David, Raymond, Victoria M., Garst, Jordan H., Erlander, Mark G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977654/ https://www.ncbi.nlm.nih.gov/pubmed/27508108 http://dx.doi.org/10.1186/s40164-016-0052-3 |
Ejemplares similares
-
Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
por: Gao, Xuejuan, et al.
Publicado: (2019) -
AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016) -
Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer
por: Matsumoto, Yoshiya, et al.
Publicado: (2022) -
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020) -
Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
por: Vaclova, Tereza, et al.
Publicado: (2021)